Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Companyâs pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.

Employees

342

Sector

Biotechnology & Medical Research

Calendar

May. 19 - Q1 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-03-14	14.62 $	-1.28%	1,689,885
25-03-13	14.81 $	-2.31%	1,047,750
25-03-12	15.16 $	-2.13%	2,345,109
25-03-11	15.49 $	+7.72%	2,575,014
25-03-10	14.38 $	-2.31%	1,813,273

Delayed Quote Nasdaq, March 14, 2025 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.62USD

Average target price

20.25USD

Spread / Average Target

+38.51%

Consensus

Profit revisions

Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2025-03-14 pm EDT			5-day change	1st Jan Change
14.62 ^USD	-1.28%		-0.68%	+4.95%

Feb. 26	Arcutis Biotherapeutics Says FDA Accepts Supplemental New Drug Application for Zoryve Cream	MT
Feb. 26	Arcutis Biotherapeutics, Inc. Announces U.S. FDA Accepts Supplemental New Drug Application for its ZORYVE (Roflumilast) Cream 0.05% for Treatment of Children Aged 2 to Moderate Atopic Dermatitis	CI

Capitalization	1.73B 1.59B 1.53B 1.34B 2.5B 151B 2.75B 17.59B 6.67B 63.61B 6.5B 6.37B 257B	P/E ratio 2025 *	-27.8x	P/E ratio 2026 *	43.9x
Enterprise value	1.29B 1.18B 1.14B 998M 1.86B 112B 2.04B 13.07B 4.95B 47.26B 4.83B 4.73B 191B	EV / Sales 2025 *	4.27x	EV / Sales 2026 *	2.68x
Free-Float	97.85%	Yield 2025 *	-	Yield 2026 *	-

Arcutis Biotherapeutics Says FDA Accepts Supplemental New Drug Application for Zoryve Cream	Feb. 26	MT
Arcutis Biotherapeutics, Inc. Announces U.S. FDA Accepts Supplemental New Drug Application for its ZORYVE (Roflumilast) Cream 0.05% for Treatment of Children Aged 2 to Moderate Atopic Dermatitis	Feb. 26	CI
Arcutis Biotherapeutics Q4 Loss Narrows, Revenue Rises	Feb. 26	MT
Arcutis Biotherapeutics, Inc., Q4 2024 Earnings Call, Feb 25, 2025	Feb. 25
Earnings Flash (ARQT) Arcutis Biotherapeutics Posts Q4 Loss $-0.09 Per Share, vs. FactSet Est of $-0.26	Feb. 25	MT
Earnings Flash (ARQT) Arcutis Biotherapeutics Reports Q4 Revenue $71.4M, vs. FactSet Est of $60.8M	Feb. 25	MT
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	Feb. 25	CI
Arcutis Biotherapeutics, Inc. Announces Publication of Positive Data from Integument-PED Trial Evaluating ZORYVE®? (roflumilast) Cream0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology	Feb. 24	CI
Arcutis Biotherapeutics Expects Fiscal Q4 Revenue to Soar Driven by Zoryve Demand	Jan. 13	MT
Arcutis Biotherapeutics, Inc. Announces Preliminary Unaudited Earnings Guidance for Fourth Quarter and Full Year 2024	Jan. 12	CI
HC Wainwright Initiates Arcutis Biotherapeutics at Buy With $19 Price Target	Dec. 30	MT
Arcutis Biotherapeutics Submits Supplemental New Drug Application to FDA for Zoryve Cream	Dec. 16	MT
Arcutis Biotherapeutics, Inc. Submits Zoryve® (Roflumilast) Cream 0.05% Supplemental New Drug Application to the Fda for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis	Dec. 16	CI

HC Wainwright Initiates Arcutis Biotherapeutics at Buy With $19 Price Target	Dec. 30	MT
Jefferies Initiates Arcutis Biotherapeutics at Buy	24-08-28	MT
Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating	24-05-15	MT
Mizuho Securities Adjusts Arcutis Biotherapeutics Price Target to $18 From $17, Maintains Buy Rating	24-05-15	MT
Mizuho Securities Raises Price Target on Arcutis Biotherapeutics to $17 From $16, Maintains Buy Rating	24-02-28	MT

Arcutis Biotherapeutics, Inc. Stock

Equities

ARQT

US03969K1088

Biotechnology & Medical Research

Valuation: Arcutis Biotherapeutics, Inc.

Chart: Arcutis Biotherapeutics, Inc.

Latest news: Arcutis Biotherapeutics, Inc.

Last Transcript: Arcutis Biotherapeutics, Inc.

Analysts' recommendations: Arcutis Biotherapeutics, Inc.

Press Releases: Arcutis Biotherapeutics, Inc.

News in other languages: Arcutis Biotherapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Arcutis Biotherapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting	Mar. 10	AQ
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting	Mar. 07	GL
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 05	AQ
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting	Mar. 03	AQ
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting	Feb. 28	GL

USA-Les valeurs à suivre à Wall Street (actualisé)	23-12-18
MORNING BRIEFING - USA/Asien	23-12-18

1 day	-1.28%
1 week	-0.68%
Current month	+6.79%
1 month	+14.40%
3 months	+15.21%
6 months	+37.15%
Current year	+4.95%

Manager	Title	Age	Since
Todd Watanabe CEO	Chief Executive Officer	57	2017-03-31
David Topper DFI	Director of Finance/CFO	67	2024-04-09
Rajvir Madan CTO	Chief Tech/Sci/R&D Officer	-	2021-05-31

Director	Title	Age	Since
Bhaskar Chaudhuri CHM	Chairman	70	2016-05-31
Patrick Heron CHM	Chairman	55	2019-11-30
Todd Watanabe BRD	Director/Board Member	57	2015-12-31

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ARCUTIS BIOTHERAPEUTICS, INC.	-1.28%	-0.68%	+33.64%	-7.12%	1.73B
VERTEX PHARMACEUTICALS INCORPORATED	+0.37%	+3.38%	+23.49%	+108.86%	130B
REGENERON PHARMACEUTICALS, INC.	-2.02%	-5.74%	-30.46%	+1.59%	71.37B
ARGENX SE	+3.03%	-0.79%	+58.42%	+115.74%	36.42B
BEIGENE, LTD.	+1.81%	+4.91%	+53.46%	+76.64%	27.77B
WUXI APPTEC CO., LTD.	+4.60%	+2.24%	+19.44%	-33.86%	25.3B
BIONTECH SE	+2.06%	-8.56%	+7.06%	-34.52%	23.87B
SUMMIT THERAPEUTICS INC.	+8.34%	+16.93%	+337.68%	+647.84%	15.34B
INSMED INCORPORATED	+1.97%	+2.22%	+190.95%	+261.08%	13.86B
GENMAB A/S	+3.44%	-14.79%	-32.34%	-36.42%	13.1B
Average	+2.23%	-0.00%	+66.13%	+109.98%	35.84B
Weighted average by Cap.	+1.19%	+0.29%	+35.16%	+89.15%

	2025 *	2026 *
Net sales	302M 277M 267M 234M 434M 26.24B 478M 3.06B 1.16B 11.07B 1.13B 1.11B 44.76B	433M 398M 383M 336M 624M 37.68B 686M 4.4B 1.67B 15.89B 1.62B 1.59B 64.27B
Net income	-65.69M -60.38M -58.12M -50.86M -94.55M -5.71B -104M -666M -253M -2.41B -246M -241M -9.74B	43.52M 40.01M 38.51M 33.7M 62.65M 3.78B 68.92M 441M 167M 1.6B 163M 160M 6.45B
Net Debt	-446M -410M -394M -345M -642M -38.75B -706M -4.52B -1.71B -16.34B -1.67B -1.64B -66.09B	-574M -527M -507M -444M -826M -49.87B -908M -5.82B -2.2B -21.03B -2.15B -2.11B -85.06B